Miranax (Naproxen Sodium)

Naproxen sodium, the active ingredient in Miranax, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral formulation for systemic use. It is employed to alleviate pain and reduce inflammation in adult patients with musculoskeletal and inflammatory conditions.

GNH USA supplies Miranax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Customers benefit from reliable logistics and dedicated technical support throughout the procurement process.

Miranax (naproxen sodium) acts as a non‑selective COX inhibitor and is indicated for several painful and inflammatory conditions.

- Osteoarthritis: reduces joint pain and swelling, improving mobility. - Rheumatoid arthritis: alleviates chronic inflammation and joint discomfort. - Ankylosing spondylitis: diminishes spinal stiffness and pain. - Acute musculoskeletal pain: provides rapid relief of sprains, strains and back pain. - Dysmenorrhea: eases menstrual cramps and associated discomfort. - Gout flares: lessens pain and inflammation during acute attacks.

Naproxen sodium may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding: potentially life‑threatening hemorrhage. - Renal impairment: reduced kidney function or acute kidney injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing naproxen sodium, clinicians should consider several precautionary measures to minimize risk.

- Assess cardiovascular risk: evaluate history of heart disease or stroke before use. - Review gastrointestinal history: avoid in patients with active ulcers or bleeding disorders. - Monitor renal function: check creatinine levels in individuals with kidney impairment. - Use lowest effective dose: limit duration to the shortest period necessary for symptom control. - Avoid use in late pregnancy: contraindicated during the third trimester due to fetal risks. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Naproxen sodium can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Selective COX‑2 inhibitors (e.g., celecoxib): additive gastrointestinal toxicity. - High‑dose aspirin: heightened risk of ulceration and bleeding.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce antihypertensive effect and impair renal function. - Diuretics: potential for decreased kidney perfusion. - Lithium: naproxen may raise lithium serum concentrations. - Methotrexate: reduced clearance leading to toxicity.